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Genetic background may contribute to
the latitude-dependent prevalence
of dermatomyositis and anti-TIF1-γ
autoantibodies in adult patients with
myositis
Joanna E. Parkes1* , Simon Rothwell2, Alexander Oldroyd2,3,4, Hector Chinoy2,4,5, Janine A. Lamb1
and The Myositis Genetics Consortium (MYOGEN)

Abstract
Background: The prevalence of dermatomyositis (DM) versus DM and polymyositis (PM) combined has been
shown to be negatively associated with latitude. This observation has been attributed to increasing exposure to
ultraviolet (UV) light towards the equator. In this study, we investigated whether differing genetic background in
populations could contribute to this distribution of DM.
Methods: Case data derived from the MYOGEN (Myositis Genetics Consortium) Immunochip study (n = 1769) were
used to model the association of DM prevalence and DM-specific autoantibodies with latitude. Control data (n = 9911)
were used to model the relationship of human leucocyte antigen (HLA) associated with DM autoantibodies and DM or
PM single-nucleotide polymorphisms (suggestive significance in the Immunochip project, P < 2.25 × 10− 5) in
healthy control subjects with latitude. All variables were analysed against latitude using ordered logistic regression,
adjusted for sex.
Results: The prevalence of DM, as a proportion of DM and PM combined, and the presence of anti-transcription
intermediary factor 1 (anti-TIF1-γ) autoantibodies were both significantly negatively associated with latitude (OR
0.96, 95% CI 0.95–0.98, P < 0.001; and OR 0.95, 95% CI 0.92–0.99, P = 0.004, respectively). HLA alleles significantly
associated with anti-Mi-2 and anti-TIF1-γ autoantibodies also were strongly negatively associated with latitude
(OR 0.97, 95% CI 0.96–0.98, P < 0.001 and OR 0.98, 95% CI 0.97–0.99, P < 0.001, respectively). The frequency of five
PM- or DM-associated SNPs showed a significant association with latitude (P < 0.05), and the direction of four of
these associations was consistent with the latitude associations of the clinical phenotypes.
Conclusions: These results lend some support to the hypothesis that genetic background, in addition to UV
exposure, may contribute to the distribution of DM.
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Background
The idiopathic inflammatory myopathies (IIMs) are a
spectrum of rare and heterogeneous autoimmune diseases causing inflammation and weakness of skeletal
muscle. Major clinical subgroups are polymyositis (PM)
and dermatomyositis (DM). The relative prevalence of
PM versus DM varies between populations, and it appears to be dependent on latitude; as latitude increases,
the relative prevalence of DM (i.e., DM/DM and PM
combined) decreases [1, 2]. This effect has been attributed to higher ultraviolet (UV) radiation levels increasing the likelihood of the development of DM over PM
towards the equator, and also increasing the prevalence
of the DM-specific autoantibody anti-Mi-2 [2–4]. UV radiation is thought to play a role in DM owing to skin
changes being more prominent on the sun-exposed parts
of the face, neck and shoulders, reports of photoaggravation of skin lesions and increased cutaneous photosensitivity compared with healthy control individuals [5, 6].
UV radiation is used in phototherapy of skin conditions
such as psoriasis as well as being a major risk factor for
skin cancer owing to its suppression of the immune system. UV radiation affects the immune system in various
ways, including DNA damage via production of ROS,
induction of cytokine signalling and induction of
T-regulatory cells [7]. Although thought to be linked to
the development of some autoimmune disorders, it is
unclear how UV radiation contributes to the pathogenesis of conditions such as DM [2].
Notably, latitude and UV radiation intensity do not
perfectly correlate, and UV exposure may depend on the
behaviour of individuals, such as whether they work indoors or outdoors. It is possible that the observed differences in DM, PM and anti-Mi-2 prevalence with latitude
could additionally be influenced by other factors, such as
the different genetic backgrounds of populations. The
most strongly associated single-nucleotide polymorphism (SNP) outside the human leucocyte antigen (HLA)
gene complex for the PM subgroup in a recent IIM
Immunochip study (rs2476601 in PTPN22) [8] demonstrates a correlation with latitude, with increasing risk allele frequency from southern to northern Europe [9].
Similarly, some HLA allele frequencies are known to
vary with latitude, such as HLA-B27, associated with ankylosing spondylitis, which is absent in populations
around the equator but increases to 40% in populations
in the far north and the Arctic [10].
The aim of this study was to explore the associations
of PM and DM prevalence and autoantibody frequencies
with latitude. In particular, we investigated whether
these “latitude-dependent” associations could instead be
attributed to genetic background rather than environmental factors by analysing the distribution of PM and
DM risk SNPs in healthy populations.
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Methods
Association of relative prevalence of PM and DM, and DM
autoantibody frequency with latitude in a large myositis
cohort

Data from the IIM Immunochip study [8] were used to
model the association of relative prevalence of PM or
DM and DM-specific autoantibody frequency with
latitude. Of the DM-specific autoantibodies, only
anti-transcription intermediary factor 1-γ (anti-TIF1-γ)
(97 positive, 1345 tested) and anti-Mi-2 (83 positive,
1471 tested) were analysed, because only a limited
number of patients were anti-SAE- (n = 29) or
anti-MDA5-positive (n = 18). Autoantibodies were tested
in various centres using immunoprecipitation, line blot
or enzyme-linked immunosorbent assays. Geographical
latitude was assigned according to the approximate latitude of the recruitment centre which contributed samples to the MYOGEN (Myositis Genetics Consortium)
Immunochip study as a proxy for latitude of origin and
disease onset [8]. Data were available from 1769 cases
(914 PM and 855 DM) from 12 countries worldwide
(Additional file 1). All individuals included in the study
were Caucasian. Juvenile cases were excluded because
some contributing centres collected only juvenile DM
cases, and this may have introduced bias into the latitudinal associations.
Analysis of association of PM and DM single-nucleotide
polymorphism risk alleles with latitude in healthy control
subjects

The risk allele frequencies of ten SNPs associated with
PM or DM (suggestive significance threshold of P <
2.25 × 10− 5) in the Immunochip study [8] were analysed
for their association with latitude using the control individuals from the study (n = 9911). Recruitment centre
information was not available for some control individuals; for these samples average latitude of the contributing country was used (see Additional file 1 for details).
U.S. control samples lacking recruitment centre information were excluded owing to the large range of
possible latitudes.
Analysis of association of HLA alleles with DM-specific
autoantibodies with latitude in healthy control subjects

HLA alleles associated with DM-specific autoantibodies
also were analysed for their association with latitude in
the Immunochip control individuals (n = 9911). In the
Immunochip data HLA-DRB1* 07:01 is strongly associated with anti-Mi-2, and HLA-DQB1*02 is strongly associated with anti-TIF1-γ (P = 4.36 × 10− 12 and P = 2.11 ×
10− 11 respectively [11], Rothwell S: Personal communication, in preparation). All associations were modelled
using ordered logistic regression, adjusted for sex.
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Analysis was carried out using STATA version 13.1 (StataCorp, College Station, TX, USA) [12].

Results
Relative prevalence of DM and frequency of anti-TIF1-γ
autoantibodies are significantly negatively associated
with latitude in adult myositis

In ordered logistic regression analysis using the IIM
Immunochip case data (n = 1769), the relative prevalence of DM (versus PM and DM combined) had a significant association with latitude (OR 0.96, 95% CI 0.95–
0.98, P < 0.001) (Additional file 2). The presence of
anti-TIF1-γ autoantibodies in the cases tested (n = 1345)
was negatively associated with latitude (OR 0.95, 95% CI
0.92–0.99, P = 0.004). However, the presence of
anti-Mi-2 autoantibodies in the cases tested (n = 1471)
was not significantly associated with latitude (Table 1).
PM and DM SNP risk alleles are significantly associated
with latitude in healthy populations

In ordered logistic regression analysis using data from
the Immunochip study controls (n = 9911), the frequency of four of eight PM-associated SNP risk alleles
showed a significant association with latitude (P < 0.05);
the three most significant associations were positively
associated. One of the two DM-associated SNPs was significantly negatively associated with latitude (Table 2).
HLA alleles associated with DM-specific autoantibodies
are significantly associated with latitude in healthy
control individuals

In ordered logistic regression analysis using control
data from the IIM Immunochip study (n = 9911),
HLA alleles associated with the DM-specific autoantibodies anti-Mi-2 and anti-TIF1-γ were strongly
negatively associated with latitude (OR 0.97, 95% CI
0.96–0.98, P < 0.001; and OR 0.98, 95% CI 0.97–0.99,
P < 0.001, respectively).
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Discussion
In this study we analysed the associations between latitude and DM relative prevalence and DM-specific autoantibody frequencies in the largest IIM cohort to date.
In addition, we analysed the association of latitude with
PM- or DM-associated SNP risk allele frequencies and
HLA alleles associated with DM autoantibodies in
healthy populations. The results confirmed that the proportion of DM increases towards the equator, with a
strong negative association with latitude. Furthermore,
we showed, for the first time, to our knowledge, that
DM-specific anti-TIF1-γ autoantibody frequency was
significantly negatively associated with latitude along
with HLA alleles associated with anti-TIF1-γ and
anti-Mi-2. However, we failed to replicate the increase in
the presence of anti-Mi-2 autoantibodies towards the
equator which was reported in a previous study (P =
0.0349) [2]. The association of anti-Mi-2 with surface
UV radiation intensity in that study was more significant (P = 0.0196) than the association with latitude
and later replicated in another study of UV radiation
[2, 3]. In addition, exposing keratinocytes to UV
radiation has been shown to increase the expression
of Mi-2 protein [13], supporting the hypothesis that
UV radiation may be associated with production of
anti-Mi-2 autoantibodies.
In the analysis of PM- and DM-associated non-HLA
SNP risk allele frequency, we found that half of the SNPs
analysed were significantly associated with latitude and
four of five were consistent with the latitude associations
of PM or DM prevalence (positive for PM and negative
for DM). Effect sizes were modest, but the ORs had tight
CIs and were statistically significant.
This study has some limitations, including the assumption that the patients’ location at disease onset and place
of birth would be similar to the location of the recruitment centres. The study was limited to one ethnic group
because the genetic association study was performed only

Table 1 Association of latitude with dermatomyositis prevalence, dermatomyositis-specific autoantibody and associated human leucocyte
antigen allele frequency
Variable

Associations with latitude, adjusted for sex
OR (95% CI)

P value

Relative prevalence of DM

0.96 (0.95, 0.98)

< 0.001

Anti-Mi-2

0.99 (0.97, 1.03)

0.927

Anti-TIF1-γ

0.95 (0.92, 0.99)

0.004

HLA-DRB1*07:01 (associated with anti-Mi-2)

0.97 (0.96, 0.98)

< 0.001

HLA-DQB1*02 (associated with anti-TIF1-γ)

0.98 (0.97, 0.99)

< 0.001

DM Dermatomyositis, HLA Human leucocyte antigen, TIF1-γ Transcription intermediary factor 1
All variables were analysed against latitude in an ordered logistic regression analysis, adjusted for sex. Relative prevalence of DM was calculated as the frequency
of DM/the frequency of polymyositis (PM) and DM combined. The proportion of autoantibodies was calculated from all adult PM and DM cases tested for that
particular autoantibody (n = 1471 tested for anti-Mi-2, n = 1345 tested for anti-TIF1-γ), derived from case data in the Immunochip study (n = 1769). HLA allele
frequencies were calculated from the Immunochip control data (n = 9911) for DM-specific autoantibody associations in the Immunochip data (HLA-DRB1*07:01
with anti-Mi-2 and HLA-DQB1*02 with anti-TIF1-γ, P = 4.36 × 10− 12 and P = 2.11 × 10− 11, respectively [11]; Rothwell S: Personal communication, in preparation)
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Table 2 Association of polymyositis- or dermatomyositis-associated single-nucleotide polymorphisms with latitude
Immunochip associations and P values for subgroups

Associations with latitude, adjusted for sex

Reported gene

Polymyositis

Dermatomyositis

OR (95% CI)

P value

rs2476601

PTPN22

7.90 × 10−11

0.05

1.08 (1.05, 1.11)

< 0.001

rs4690220

SLC26A1 | IDUA

7.47 × 10−6

0.03

1.02 (1.01, 1.02)

0.001

Variable
PM associations

−6

rs7956536

UBE3B | MMAB

3.66 × 10

0.67

1.01 (1.00, 1.02)

0.004

rs17799348

FAM167A | BLK

4.13 × 10−6

0.32

0.99 (0.98, 0.99)

0.035

−6

rs1420095

IL18R1

6.16 × 10

0.87

0.99 (0.98, 1.01)

0.334

rs2286896

NAB1

3.76 × 10−6

0.58

0.99 (0.98, 1.01)

0.434

−6

rs9905921

LOC728073 | RPL38

2.01 × 10

0.10

0.99 (0.99, 1.01)

0.748

rs7535818

RGS1

1.37 × 10−5

0.14

0.99 (0.99, 1.01)

0.897

ROPN1L | ANKRD33B

0.5

4.49 × 10−6

0.99 (0.98, 0.99)

0.012

0.99 (0.98, 1.00)

0.081

DM associations
rs4702698
rs570676

PRR5L | TRAF6

0.01

−7

6.23 × 10

DM Dermatomyositis, PM Polymyositis
All variables were analysed against latitude in an ordered logistic regression analysis, adjusted for sex. Single-nucleotide polymorphisms (SNPs) identified as having
suggestively significant P values (P < 2.25 × 10−5) for either PM or DM in the Immunochip study [8] were used. SNP risk allele frequencies were calculated from the
Immunochip study control data (n = 9911)

in Caucasian samples. In addition, samples were collected
within a limited range of latitudes, and the cases and controls were not from exactly the same populations. Studies
with collection of disease onset and place of birth data
along with UV exposure data in a larger multi-ethnic IIM
and control cohort spread over a greater range of latitudes
could elucidate whether latitude associations are due to
population genetic background or environmental factors.

Conclusions
Overall, these results lend some support to the hypothesis that different genetic backgrounds of populations
may contribute to the increased prevalence of DM toward the equator, in addition to, or instead of, increasing
UV radiation exposure levels.
Additional files
Additional file 1: Table S1. Immunochip study data included in analyses.
Assigned latitude and numbers of PM, DM and controls at each centre
included in the study. (DOCX 25 kb)
Additional file 2: Figure S1. The association of relative dermatomyositis
(DM) prevalence, frequency of DM-associated autoantibodies, HLA alleles
and single-nucleotide polymorphisms with latitude. Two-way linear
prediction plot with 95% CIs was produced using STATA version 13.1
software. Data for DM as a proportion of PM and DM (n = 1769), frequency
of anti-TIF1-γ in all samples tested (n = 1345) and frequency of anti-Mi-2 in
all samples tested (n = 1471) are derived from the Immunochip study [8].
Frequencies of HLA-DQB1*02, HLA-DRB1*07:01, rs4702698 and rs570676 are
derived from the Immunochip control data (n = 9911). (TIF 2203 kb)
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